News Shares Technology

Cassava Sciences Rise Dramatically This Week

Sponsored

Cassava Sciences (NASDAQ:SAVA) news for Friday insider that is concerning has SAVA stock increasing.

colorful pills and vials sitting on a table
Source: Bukhta Yurii / Shutterstock.com
The insider buying is revealed in filings with most of the U.S. Securities and Exchange Commission. Two filings that are split that members of the company’s leadership group picked up extra stocks of SAVA stock on Thursday.

The filing that is very first that Sanford Robertson, member of the Cassava Sciences Board of Directors, bought a total of 213,719 shares of SAVA stock for $6.98 each. After that deal, he now has 876,342 shares associated with the stock.

The filing that is second SAVA stock acquisitions created by Cassava Sciences CFO Eric Schoen. He purchased 10,000 shares straight for $7.03 each. The CFO also acquired 2,00 shares indirectly for $7.04 each through Schoen Family LLC. This has him keeping 27,300 stocks of SAVA stock after both of those acquisitions.

It’s worth pointing out that this news of insider buying comes simply a few of days after Cassava Sciences announced results from a trial that is clinical. This Phase 2b trial that is clinical evaluating the utilization of sumifilam in treating clients with Alzheimer’s. This company has shown much promise in the past concerning this topic, and that doesn’t seem to have changed recently.

Cassava Sciences noted that it saw incredibly positive results from the study that is current. Which includes increases being seeing a few biomarkers for treating Alzheimer’s. It remarked that this is the complete time that is very first single drug has had the opportunity to definitely affect multiple Alzheimer’s biomarkers.

SAVA stock ended up being up 38.4% at the time of Friday afternoon, which pushes it to a fresh high that is 52-week. Cassava Sciences (NASDAQ:SAVA) news for Friday insider.

Sponsored

Dayanira Munoz

With experience in the finance industry exceeding 7 years, Dayanira’s impressive CV includes key positions at leading companies such as Merrill Lynch, Credit Suisse, and Morgan Stanley. She has held a wide range of key roles across research, sales, and trading, and has worked with both retail and institutional clients. Over her blossoming career, Dayanira has gained extensive exposure to equities, the Forex, and fixed income markets, putting her in a unique position. This varied and specialized experience allows her to provide expert insights, suggestions, and risk-management strategies for colleagues and clients. Previously, Dayanira graduated in Applied Finance at the University of Barcelona and is currently studying for her Master’s degree.

Related Posts

Sponsored
Sponsored